Feasibility of surgical orchiectomy in prostate cancer patients on long term luteinizing hormone-releasing hormone (LHRH) agonist therapy. Population-adjusted network meta-analyses (NMA) to evaluate ...

[99mTc]Tc-iPSMA SPECT/CT as an alternative to PET imaging for decision making in prostate cancer patients. PREP registry: Key findings. Total (n=4135) Cohort 1 (n=255): BF within 3 months from RP and ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Wolfgang P.

Telix Pharmaceuticals Ltd.’s prostate cancer PET imaging agent Illuccix has been approved by the Danish Medicines Agency.

Telix Pharmaceuticals has announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Ivan de Kouchkovsky discussing the impact of baseline PSMA PET in patients with metastatic ...

Telix Pharmaceuticals Limited today announces that the United Kingdom Medicines and Healthcare Products Regulatory Agency has ...

UK MHRA grants marketing authorization to Telix’s prostate cancer PET imaging agent, Illuccix: Melbourne, Australia Friday, February 14, 2025, 10:00 Hrs [IST] Telix, a commercia ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent Illuccix® ...

This highlights the high unmet need for novel diagnostics in prostate cancer and the high quality of data we presented to the FDA. “The market for first-generation diagnostic PSMA PET today is ...